State of New Jersey Common Pension Fund D Has $4.32 Million Stake in United Therapeutics Corporation $UTHR

Key Points

• The State of New Jersey Common Pension Fund D has reduced its holdings in United Therapeutics Corporation (UTHR) by 9.3%, selling 1,442 shares and owning 13,997 shares worth $4,315,000 at the end of the quarter.
• Institutional investors own approximately 94.08% of UTHR, with several firms like Allianz Asset Management and LPL Financial significantly increasing their stakes in the first quarter.
• Analysts have varied ratings for UTHR, with most recent adjustments including JPMorgan lowering its price target to $330 and UBS increasing it to $415, indicating mixed market sentiment.

State of New Jersey Common Pension Fund D lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 9.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,997 shares of the biotechnology company's stock after selling 1,442 shares during the quarter. State of New Jersey Common Pension Fund D's holdings in United Therapeutics were worth $4,315,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in UTHR. Mariner LLC raised its position in shares of United Therapeutics by 7.7% in the fourth quarter. Mariner LLC now owns 4,200 shares of the biotechnology company's stock valued at $1,482,000 after buying an additional 299 shares during the last quarter. Jump Financial LLC acquired a new stake in shares of United Therapeutics during the fourth quarter valued at about $369,000. NewEdge Advisors LLC boosted its stake in shares of United Therapeutics by 124.6% in the fourth quarter. NewEdge Advisors LLC now owns 3,027 shares of the biotechnology company's stock valued at $1,068,000 after purchasing an additional 1,679 shares during the period. Commerce Bank boosted its stake in shares of United Therapeutics by 7.6% in the fourth quarter. Commerce Bank now owns 1,408 shares of the biotechnology company's stock valued at $497,000 after purchasing an additional 100 shares during the period. Finally, Freedom Investment Management Inc. lifted its stake in United Therapeutics by 6.5% in the fourth quarter. Freedom Investment Management Inc. now owns 869 shares of the biotechnology company's stock worth $307,000 after acquiring an additional 53 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the sale, the director owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This trade represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 92,681 shares of company stock valued at $28,014,609 in the last ninety days. 10.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Bank of America dropped their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. HC Wainwright set a $400.00 price objective on United Therapeutics and gave the stock a "buy" rating in a research report on Thursday, July 31st. UBS Group upped their target price on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Finally, Wells Fargo & Company cut their price target on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a report on Thursday, July 31st. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $382.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded up $1.57 during midday trading on Friday, reaching $312.23. The company had a trading volume of 576,473 shares, compared to its average volume of 751,685. The stock's fifty day moving average price is $297.01 and its 200-day moving average price is $307.67. The stock has a market capitalization of $14.08 billion, a P/E ratio of 12.19, a PEG ratio of 4.71 and a beta of 0.57. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same period in the prior year, the firm earned $5.85 EPS. The business's revenue for the quarter was up 11.7% compared to the same quarter last year. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.